The National Health Surveillance Agency (Anvisa) held this Thursday (6) a series of meetings to analyze Coronavac data on children. According to the Agency, the meeting is part of the evaluation of the Instituto Butantan’s request for the use of the immunizing agent for children and adolescents aged between 3 and 17 years.
The activity was divided into three parts: the first included the presentation of effectiveness studies carried out by the Oswaldo Cruz Foundation (Fiocruz). Afterwards, the data were discussed by external experts invited by Anvisa.
The debate was attended by representatives of the Brazilian Society of Infectious Diseases (SBI), the Department of Infectology of the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Immunology (SBI) and the Brazilian Association of Public Health (Abrasco).
Finally, Anvisa’s technical team held a meeting with Instituto Butantan, technicians from Chile and Sinovac. According to the Agency, the meetings “are another step in the analysis of the vaccine” and the data presented “represent an advance in the work”.
Butantan asked Anvisa for authorization to use Coronavac in children aged 3 to 17 in December, but the Agency demanded more data from the Institute stating that those provided were not sufficient for the guarantee.
In Brazil, Pfizer’s immunizing agent is the only one approved for pediatric use. This Wednesday (5), the Ministry of Health presented the details of how the vaccination of children between 5 and 11 years old will be done.
Reference: CNN Brasil
